Dr. David Bender, MD
Claim this profileUniversity of Iowa/Holden Comprehensive Cancer Center
Studies Ovarian Cancer
Studies Endometrial Adenocarcinoma
16 reported clinical trials
41 drugs studied
Area of expertise
1Ovarian Cancer
BRCA1 positive
Stage IV
Stage II
2Endometrial Adenocarcinoma
Stage IV
Stage I
Stage III
Affiliated Hospitals
Clinical Trials David Bender, MD is currently running
Mirvetuximab + Bevacizumab
for Ovarian Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Recruiting2 awards Phase 3
M1774 + ZEN-3694
for Ovarian and Endometrial Cancer
This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M1774 and ZEN-3694 combined together has demonstrated to be better than either drug alone in killing ovarian tumor cells.
Recruiting1 award Phase 115 criteria
More about David Bender, MD
Clinical Trial Related2 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments David Bender, MD has experience with
- Olaparib
- Bevacizumab
- External Beam Radiation Therapy
- Pembrolizumab
- Cediranib Maleate
- Durvalumab
Breakdown of trials David Bender, MD has run
Ovarian Cancer
Endometrial Adenocarcinoma
Uterine Cancer
Ovarian Carcinoma
Ovarian Adenocarcinoma
- Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
- Chemotherapy + Immunotherapy for Recurrent Ovarian Cancer
- M1774 + ZEN-3694 for Ovarian and Endometrial Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Bender, MD specialize in?
David Bender, MD focuses on Ovarian Cancer and Endometrial Adenocarcinoma. In particular, much of their work with Ovarian Cancer has involved BRCA1 positive patients, or patients who are Stage IV.
Is David Bender, MD currently recruiting for clinical trials?
Yes, David Bender, MD is currently recruiting for 5 clinical trials in Iowa City Iowa. If you're interested in participating, you should apply.
Are there any treatments that David Bender, MD has studied deeply?
Yes, David Bender, MD has studied treatments such as Olaparib, Bevacizumab, External Beam Radiation Therapy.
What is the best way to schedule an appointment with David Bender, MD?
Apply for one of the trials that David Bender, MD is conducting.
What is the office address of David Bender, MD?
The office of David Bender, MD is located at: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa 52242 United States. This is the address for their practice at the University of Iowa/Holden Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.